Compare Enveric Biosciences Inc (ENVB) vs Range Resources Corporation Common Stock (RRC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Range Resources Corporation Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.2 (market cap $6.27M), while Range Resources Corporation Common Stock trades at $41.78 (market cap $9.93B). The key difference: Range Resources Corporation Common Stock is far larger — about 1583.7× Enveric Biosciences Inc's market cap, and Range Resources Corporation Common Stock pays a 0.94% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Range Resources Corporation Common Stock for 0 Days on average.
| ENVB | RRC | |
|---|---|---|
Market Cap | $6.27M | $9.93B |
Volume | 100,675 | 2,413,752 |
Sector | Health | Energy |
52-Week High | $10.80 | $47.65 |
52-Week Low | $1.27 | $33.43 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$2.03M | $10.94B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.40, down 4.76% with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and no revenue in 2025, though it has consistently beaten EPS estimates. Recent news highlights patent approvals and positive preclinical data for its neuroplastogenic therapeutics.
The outlook remains speculative given the lack of revenue and negative cash flow from operations. Analyst consensus is 75% buy, but high business execution risks and dependence on drug development success pose significant challenges for near-term shareholder value.
Range Resources (RRC) trades at $42.48, up 2.56% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows solid fundamentals with a P/E of 11.73 and net income margin of 26.32%, while technical indicators signal neutral momentum near key resistance at $43. Recent institutional buying and positive analyst coverage (38.71% buy ratings) support the bullish case.
Outlook remains positive with Q3 2026 earnings expected at $0.776 per share and consensus price target of $44.00 offering 3.6% upside. Risks include energy price volatility and negative net cash flow of -$304M in 2025, though improved 2026 projections show operating cash flow growth to $1.4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Range Resources Corporation Common Stock
Range Resources Corporation is an independent natural gas and natural gas liquids producer operating in the Appalachian Basin, primarily the Marcellus Shale in Pennsylvania, handling drilling, completion, and gathering and transportation connections for its production.
Read more on RRC →
